02/21
Headlines

NASDAQ:VVUS

Hot Watch List: VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Biogen Idec Inc (NASDAQ:BIIB)

Mark DeFrance03 mins

Drugmaker Vivus Inc. (NASDAQ:VVUS) said Thursday it has filed a lawsuit against Actavis PLC and its affiliates in a New Jersey federal court over its bid with the U.S. Food and Drug Administration to sell a generic version of company’ prescription weight-loss drug Qsymia. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -0.19% in last session and…

Read More

Hot Watch List: Teva Pharmaceutical Industries (NYSE:TEVA), Vodafone Group (NASDAQ:VOD), VIVUS (NASDAQ:VVUS), ConocoPhillips (NYSE:COP), BP plc (ADR) (NYSE:BP)

Kevin Long03 mins

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food…

Read More
Gilead Sciences GILD NASDAQ:GILD

Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton03 mins

InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc…

Read More

Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Jayne Crisman02 mins

Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was…

Read More
Gilead Sciences GILD NASDAQ:GILD

Unusual Volume At Healthcare: VIVUS (NASDAQ:VVUS), Span-America Medical Systems (NASDAQ:SPAN), Cyberonics (NASDAQ:CYBX), RXi Pharmaceuticals Corp (NASDAQ:RXII)

Jayne Crisman02 mins

VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.23. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 3.34% in last session and finished the day at $ 5.26. Traded volume was 2,821,422 shares in the last…

Read More

Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Chris Lewis02 mins

VIVUS Inc (NASDAQ:VVUS) will be announcing its Q114 earnings results on Monday, May 5th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $11.40 million for the quarter. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -2.12% in last session and finished the day at $5.09. Traded volume was 1.34million shares in…

Read More